Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
40.96
-0.68 (-1.63%)
Apr 16, 2026, 4:00 PM EDT - Market closed
Qiagen Employees
Qiagen had 5,700 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5,700
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$366,666
Profits / Employee
$74,540
Market Cap
8.47B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5,700 | 0 | - |
| Dec 31, 2024 | 5,700 | -267 | -4.47% |
| Dec 31, 2023 | 5,967 | -211 | -3.42% |
| Dec 31, 2022 | 6,178 | 150 | 2.49% |
| Dec 31, 2021 | 6,028 | 418 | 7.45% |
| Dec 31, 2020 | 5,610 | 514 | 10.09% |
| Dec 31, 2019 | 5,096 | 144 | 2.91% |
| Dec 31, 2018 | 4,952 | 264 | 5.63% |
| Dec 31, 2017 | 4,688 | 4 | 0.09% |
| Dec 31, 2016 | 4,684 | 125 | 2.74% |
| Dec 31, 2015 | 4,559 | 220 | 5.07% |
| Dec 31, 2014 | 4,339 | 324 | 8.07% |
| Dec 31, 2013 | 4,015 | 16 | 0.40% |
| Dec 31, 2012 | 3,999 | 61 | 1.55% |
| Dec 31, 2011 | 3,938 | 351 | 9.79% |
| Dec 31, 2010 | 3,587 | 92 | 2.63% |
| Dec 31, 2009 | 3,495 | 454 | 14.93% |
| Dec 31, 2008 | 3,041 | 379 | 14.24% |
| Dec 31, 2007 | 2,662 | 708 | 36.23% |
| Dec 31, 2006 | 1,954 | 365 | 22.97% |
| Dec 31, 2005 | 1,589 | 267 | 20.20% |
| Dec 31, 2004 | 1,322 | -231 | -14.87% |
| Dec 31, 2003 | 1,553 | -98 | -5.94% |
| Dec 31, 2002 | 1,651 | 94 | 6.04% |
| Dec 31, 2001 | 1,557 | 242 | 18.40% |
| Dec 31, 2000 | 1,315 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Labcorp Holdings | 71,000 |
| Quest Diagnostics | 57,000 |
| ICON Public Limited Company | 41,900 |
| Charles River Laboratories International | 19,700 |
| Revvity | 11,000 |
| Illumina | 10,080 |
| RadNet | 9,276 |
| Medpace Holdings | 6,200 |
QGEN News
- 10 hours ago - QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026 - Business Wire
- 2 days ago - QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel - Business Wire
- 16 days ago - Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis - Business Wire
- 27 days ago - Qiagen Announces Form 20-F Annual Report Filing for 2025 Results - Business Wire
- 4 weeks ago - QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention - Business Wire
- 5 weeks ago - QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System - Business Wire
- 2 months ago - Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery - Business Wire
- 2 months ago - QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars - Business Wire